Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Study of HH-1270 in Healthy Chinese Subjects

17. november 2026 oppdatert av: Huahui Health

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants

This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.

MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.

Studietype

Intervensjonell

Registrering (Antatt)

88

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100191
        • Rekruttering
        • Peking University Third Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
  • Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
  • Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
  • Participants must agree to take adequate and effective contraceptive measures.
  • Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).

Exclusion Criteria:

  • Individuals with severe systemic diseases, infectious diseases, or mental disorders.
  • Clinically significant electrocardiogram (ECG) abnormalities.
  • History of clinically significant drug allergy or atopic allergic diseases.
  • Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
  • Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
  • History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
  • Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
  • Blood donation ≥400 mL within 3 months before screening.
  • Participation in another interventional clinical trial within 3 months before screening.
  • Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
  • Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
  • Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
  • Inability to accept standardized diet management at the study center.
  • Participants who are breastfeeding or have a positive pregnancy test before the first dose.
  • Participants deemed unsuitable for participation in the study by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: HH-1270 group

SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

Placebo komparator: Placebo group

SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: up to 15/21 days in SAD/MAD

Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

up to 15/21 days in SAD/MAD
Clinically significant abnormalities
Tidsramme: up to 14/21 days in SAD/MAD

Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0.

up to 14/21 days in SAD/MAD

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Area Under the Plasma Concentration Versus Time Curve (AUC)
Tidsramme: up to 8/14 days in SAD/MAD

AUC of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Maximum Plasma Concentration (Cmax)
Tidsramme: up to 8/14 days in SAD/MAD

Cmax of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Time to Reach Maximum Plasma Concentration (Tmax)
Tidsramme: up to 8/14 days in SAD/MAD

Tmax of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent Terminal Elimination Half-life (T1/2)
Tidsramme: up to 8/14 days in SAD/MAD

T1/2 of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent Plasma Clearance (CL/F)
Tidsramme: up to 8/14 days in SAD/MAD

CL/F of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent volume of distribution(Vd/F)
Tidsramme: up to 8/14 days in SAD/MAD

Vd/F of HH-1270 in plasma

up to 8/14 days in SAD/MAD
To evaluate the TBA level
Tidsramme: up to 15/21 days in SAD/MAD

TBA level for each collection point

up to 15/21 days in SAD/MAD
To evaluate the CP-1 level
Tidsramme: up to 15/21 days in SAD/MAD

CP-1 level for each collection point

up to 15/21 days in SAD/MAD

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To evaluate QTc change
Tidsramme: up to 8 days in SAD

QTc values in each collection point

up to 8 days in SAD

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. oktober 2026

Primær fullføring (Antatt)

5. februar 2027

Studiet fullført (Antatt)

6. juli 2027

Datoer for studieregistrering

Først innsendt

9. oktober 2026

Først innsendt som oppfylte QC-kriteriene

9. oktober 2026

Først lagt ut (Faktiske)

15. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • HH1270-101

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere